Trial Profile
Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 27 Jan 2022
Price :
$35
*
At a glance
- Drugs Docosahexaenoic acid (Primary)
- Indications Cognition disorders
- Focus Adverse reactions; Therapeutic Use
- 18 Mar 2021 Status changed from active, no longer recruiting to completed.
- 04 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.
- 04 Feb 2019 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.